Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

FORT LEE, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX) (the "Company"), a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

"We are excited about the proven potential of NLX-P101, our Parkinson's disease gene therapy product, and continue to move forward with further definitive development," said Clark A. Johnson, President and Chief Executive Officer of the Company.  "Additionally, landmark research recently published in the journal Science Translational Medicine utilized our exclusively licensed gene therapy approach to demonstrate the importance of the p11 gene in modulating depression in mice, reversing depressive behavior of animals lacking the p11 gene.  We are extremely excited by these results, which support expanded possibilities for the development of p11 gene therapy for therapeutic use, and consider them a testament to the future commercial success of our gene therapy platform in diseases of the brain."

For the three months ended September 30, 2010, the Company reported a net loss of $2.3 million, as compared with a net loss of $3.5 million for the three months ended September 30, 2009.  Net loss for the third quarter of 2010 includes charges for the change in estimated fair value of derivative financial instruments related to warrants previously issued in connection with the Company's Series C Convertible Preferred Stock (the "Series C Stock") and the Company's Series D Convertible Preferred Stock (the "Series D Stock") of $0.3 million.  Net loss for the third quarter of 2009 includes income for the change in estimated fair value of derivative financial instruments related to warrants previously issued in connection with the Seri
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... NESS ZIONA, Israel , ... today announced that results from a phase I study ... study in advanced Parkinson,s patients, of ND0612, were presented ... Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug ... (SC) delivery patch that would maintain constant levodopa plasma ...
(Date:6/19/2013)... 19, 2013  This year alone, The Leukemia & ... projects with one goal in mind: Discovering lifesaving therapies ... Training" (TNT), a flagship LLS fundraising campaign and the ... marking its landmark 25 th anniversary. To date, ... in research to discover and deliver breakthrough cancer treatments ...
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4
... events organiser UBM Live , a division of UBM ... CPhI Worldwide and collocated events will be hosted in Madrid, ... for contract and outsourced services and logistics, P-MEC for pharmaceutical ... line-up, InnoPack for pharmaceutical packaging needs. The events will run ...
... 2011 Reportlinker.com announces that a new ... catalogue: Specialty Pharmaceutical Industry ... http://www.reportlinker.com/p0512130/Specialty-Pharmaceutical-Industry---2011-Yearbook.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Specialty Pharmaceutical Industry ... GBI Research,s "Specialty Pharmaceutical ...
Cached Medicine Technology:CPhI Worldwide, ICSE, P-MEC and InnoPack Announce 2012 Events Location 2CPhI Worldwide, ICSE, P-MEC and InnoPack Announce 2012 Events Location 3Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 2Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 3Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 4Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 5Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 6Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 7Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 8Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 9Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 10Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 11Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 12Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 13Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 14Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 15Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 16
(Date:6/19/2013)... (PRWEB) June 19, 2013 Kansas City will host ... Main Street Day . A section of Main Street in ... during the afternoon of the event. The Main Street Corridor ... event, which will help Kansas City join the ranks of dozens ... as a tool to foster community vibrancy and active lifestyles. , ...
(Date:6/19/2013)... In 2011, the value of the ... Generic drugs form the largest sector, accounting for nearly ... industry is a significant contributor to the local economy; ... Approximately 50% of the total domestic chemical industry output ... Galenika and Zdravlje Actavis are key participants in the ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of ... announced today the publication of the National Osteoporosis ... management of osteoporosis in postmenopausal women and older ... Published in 2009 in Maturitas , the ... update is timely with an additional focus on ...
(Date:6/19/2013)... Next Thursday, June 27, 2013, ... organization, and Muzzy Lane Software , a ... the Games for Health community to their interactive ... toward students in grades 4-7 and designed to ... positive choices. The game is part of a ...
(Date:6/19/2013)... Maui'd Forever , Hawaii's premiere ... an effective and cost effective way to provide for ... up with Tom Barefoot’s Tours providing an activity agent ... Hawaii’s activities. , They have just released a new ... lowest prices on their Hawaii activities. , Maui’d ...
Breaking Medicine News(10 mins):Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2
... N.J., Oct. 8 QMed, Inc., (Nasdaq:,QMED) today announced ... plan,customer for an additional three years. Under the terms ... for stroke and coronary,heart disease. In addition, the Company ... and financial performance measures. Jane Murray, QMed president ...
... SAN DIEGO, Oct. 8 The Sidney ... Sparhawk Corporation to raise,funds through a Sparhawk e-Fundraising ... alliance, supporters of SKCC can help raise funds ... http://skcc.org/shop . The eMall has links to hundreds ...
... Oct. 8 A good night,s sleep,is an ... estimated 70,million Americans complain of sleeplessness. This October, ... is offering,advice to help consumers select comfortable mattresses ... neck pain., "Americans spend one-third of their ...
... Oct. 8 Beginning in October, Concentra,("Concentra" or the ... For What Ails,You. This new theme is at the ... centers to various communities in the coming,year, beginning with ... area. The For What Ails You campaign is ...
... IPF Patients Across U.S. to Hear ... from Top Experts, ... people who suffer from Idiopathic Pulmonary Fibrosis (IPF),is the limitation the disease ... Pulmonary Fibrosis (CPF) overcomes that,obstacle for these patients by allowing them to ...
... Enhancements for Long-Term Care Facilities Enable More Proactive Care ... Help Maximize Reimbursement ... Inc.,announces the launch of AccuNurse Version 2.0, for voice-powered, ... care (LTC) industry. The enhanced features of AccuNurse ...
Cached Medicine News:Health News:QMed, Inc. Extends Agreement & Receives $550,000 Performance Bonus 2Health News:Sidney Kimmel Cancer Center to Boost Revenue Through Support From E-Fundraising Mall 2Health News:Proper Mattress Can Improve Sleep Comfort, Reduce Pain, Says American Chiropractic Association 2Health News:Proper Mattress Can Improve Sleep Comfort, Reduce Pain, Says American Chiropractic Association 3Health News:Concentra Offers a Cure 'For What Ails You' 2Health News:CPF 'Living with IPF' Patient Seminar to be Webcast Live October 13, 2007 2Health News:CPF 'Living with IPF' Patient Seminar to be Webcast Live October 13, 2007 3Health News:Vocollect Healthcare Systems Launches AccuNurse(R) Version 2.0 2Health News:Vocollect Healthcare Systems Launches AccuNurse(R) Version 2.0 3
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
...
Medicine Products: